Theranos Judge Wrestles With How Holmes Played to the Media
(Bloomberg) -- A judge is grappling with a request by U.S. prosecutors to add news articles about Theranos Inc. back in its up-and-coming days to the mound of evidence they're using against founder and former chief executive officer Elizabeth Holmes when she goes to trial this summer.
Lawyers for Holmes are fighting to keep a jury from seeing the stories, as many as 50 in all, some of them quite bullish about the blood-testing startup's prospects as a health-care breakthrough.
The government is trying to show that overheated news coverage of Theranos was part of the alleged fraud Holmes is charged with -- that she manipulated the media to whip up an investor frenzy in the company, which peaked at a valuation of $9 billion in 2014 before it collapsed into insolvency.
“The articles made it a lot easier for these investors to be defrauded,” Assistant U.S. Attorney John Bostic said during a marathon hearing in San Jose, California, over what evidence will be allowed into a trial that starts Aug. 31 with jury selection and is expected to last about four months.
“They didn't want to miss out on what, according to the coverage, was going to be a lucrative investment opportunity,” Bostic said. Holmes “exploited that favorable coverage and paved the way for the fraud.”
Read More: The Spectacular Rise and Fall of Elizabeth Holmes and Theranos
Holmes's criminal trial has been repeatedly delayed because of the pandemic and, more recently, her pregnancy. She appeared for three consecutive days this week before U.S. District Judge Edward Davila, who is winnowing the evidence jurors will consider.
Lawyers for Holmes seemed to agree the jury will hear from journalist Roger Parloff, who wrote a 2014 profile of Holmes in Fortune magazine and a December 2015 follow-up for its website titled “How Theranos Misled Me.” A doctor named Eric Topol, who interviewed Holmes in 2013 for a piece in an online medical news site titled “Creative Disruption? She's 29 and Set to Reboot Lab Medicine,” may also testify.
The remaining articles shouldn't be permitted because they make subjective observations and rely on or quote anonymous sources, and because Holmes isn't responsible for their content, one of her lawyers, Patrick Looby, told Davila. The authors also won't be at the trial for cross-examination, he added, putting the defense at an improper disadvantage.
“These articles have no place as evidence in this trial,” Looby said.
Davila maintained his typically genial but conservative demeanor with lawyers, revealing little about which articles he'll permit prosecutors to use. He observed that what gets published in modern media is often determined by editorial “whims.”
“Is the court going to be put in the position of executive editor?” he mused.
Looby cautioned the judge that the sheer volume of news stories prosecutors want to make available as evidence is an unfair burden in preparing Holmes's defense. He also challenged the government's characterization of Holmes as someone at the “center of the media ecosystem” who possessed the power to manipulate articles as the “puppeteer of their own statements.”
That's “outdated,” he said.
Read More: Fighting Theranos Charges, Holmes Blames Advocacy Journalism
Bostic brought up another news story that Holmes's team isn't eager for the jury to see: Wall Street Journal reporter John Carreyrou's 2015 expose that is widely credited with pulling the curtain back on blood testing at Theranos.
That Holmes continued to promote the accuracy of blood-testing by Theranos even after the Journal story revealed deep problems with the company's technology shows that she “doubled down on the previous misrepresentations,” the prosecutor said.
Holmes's lies to the media, and her refusal to correct them even when confronted by a concerned Theranos lawyer, served as “an important tool the defendant used to commit the fraud in this case,” Bostic said. “The desire to be famous, to receive this praise, was part of her motive in her scheme to defraud.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.